Danger for UK healthcare spending may not be from rising drugs prices or from reducing the ability of the NHS to ne… https://t.co/CS57bMLEKu
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Our pricing and reimbursement research presented at ISPOR Europe
14 November 2018
Milena Izmirlieva
In research, presented at the ISPOR Europe meeting in Barcelona on 13 October, Associate Director Milena Izmirlieva examines the impact of securing marketing approval under an expedited pathway on pricing and reimbursement outcomes.
Related Posts
-
-
-
-
-
-
-
-
Explore
RELATED INDUSTRIES & TOPICS
Follow Us
Germany’s health minister Jen Spahn is seeking to resolve a long-running dispute with the European Commission over… https://t.co/7A8HWXxOJs
We are at ISPOR! To find out more about our nuanced insights on IRP policy evolution, please check out the latest… https://t.co/XdatTuUwts
Slovakia approved legislation to curtail alleged manufacturer attempts to circumvent IRP-related price reductions b… https://t.co/qAANBeyyyN